New RNA vaccine trial targets deadly brain tumors

NCT ID NCT06389591

Recruiting now Disease control Sponsor: University of Florida Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests whether RNA-lipid particle vaccines can be safely made and given to adults with recurrent glioblastoma, an aggressive brain cancer. The vaccines are designed to teach the immune system to attack tumor cells. The study will enroll 24 participants and focus on safety and manufacturing feasibility.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RNA-lipid particle (RNA-LP) vaccines (pp65 RNA and personalized tumor mRNA)
What this could lead to: If this trial succeeds, it could point toward a new treatment option for recurrent glioblastoma, a brain cancer with few effective therapies.
What could go wrong: This is a very early phase 1 trial with only 24 participants, so it is too small to prove effectiveness. The vaccines may not trigger a strong enough immune response or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT GLIOBLASTOMA

Contacts and locations

Locations

UF Health
RECRUITING

Gainesville, Florida, 32608, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.